Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Nuvation Bio announced that taletrectinib (IBTROZI) has been added to the NCCN Clinical Practice Guidelines for CNS Cancers as a systemic therapy option for ROS1+ NSCLC patients with brain metastases. The drug had previously received NCCN recommendation as a Preferred Agent for ROS1+ NSCLC in June 2025 following its FDA approval.
Key figures
- Drug Name
- taletrectinib (IBTROZI)
- Ros1 prevalence nslc
- 2%
- Cns metastases previously treated
- 50%
- Brain mets incidence metastatic ros1
- 35%
- Intracranial response rate tki naive
- 76.5%
- Intracranial response rate tki pretreated
- 65.6%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.